|  | 1-year survival rate (%) | 3-year survival rate (%) | 5-year survival rate (%) | Median OS (months) | P value |
---|---|---|---|---|---|---|
Sex | Male | 92 | 88 | 52 | 63 | Â |
 | Female | 100 | 50 | 50 | 96 | 0.479 |
Age | Â | Â | Â | Â | Â | Â |
 | ≤10 | 100 | 93 | 53 | 63 |  |
 | >10 | 86 | 64 | 50 | 66 | 0.899 |
Anemia | No | 100 | 96 | 63 | 67.33 | Â |
 | Yes | 60 | 20 | 0 | 25 | <0.001 |
Tumor size | Â | Â | Â | Â | Â | Â |
 | ≤5 | 100 | 91 | 91 | 88.5 |  |
 | >5 | 89 | 78 | 28 | 52 | <0.001 |
Regional nodes | Â | Â | Â | Â | Â | Â |
 | Negative | 96 | 87 | 61 | 67 |  |
 | Positive | 83 | 67 | 17 | 54 | 0.033 |
Status | Â | Â | Â | Â | Â | Â |
 | Local | 100 | 95 | 75 | 76 |  |
 | Metastatic | 78 | 56 | 0 | 39 | <0.001 |
Primary sites | Â | Â | Â | Â | Â | Â |
 | Paratesticular | 90 | 80 | 70 | 82 |  |
 | Prostate | 88 | 88 | 38 | 52 |  |
 | Bladder | 100 | 100 | 43 | 61 |  |
 | Vagina | 100 | 50 | 50 | 96 | 0.349 |
Sites | Non-B/P | 93 | 71 | 64 | 82 | Â |
 | B/P | 93 | 87 | 40 | 59 | 0.084 |
Staging | Â | Â | Â | Â | Â | Â |
 | I | 100 | 90 | 90 | 88 |  |
 | II | 100 | 100 | 83 | 67 |  |
 | III | 100 | 100 | 25 | 58 |  |
 | IV | 78 | 56 | 0 | 39 | <0.001 |